SCHEMBL4901409

SCHEMBL4901409

Cc1ccc(Cn2c(-c3ccc(-c4ccc5[nH]c(C(=O)O)cc5c4)cc3)cc(C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.46
NR1H2 P55055 3/20 0.46
NR1H3 Q13133 3/20 0.46
PIN1 Q13526 1/20 0.41
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
ATM Q13315 1/20 0.38
MAPT P10636 3/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
DDR1 Q08345 1/20 0.33
ABCB1 P08183 1/20 0.33
KDM4E B2RXH2 4/20 0.33
MMP2 P08253 1/20 0.33
MMP13 P45452 1/20 0.33
MMP14 P50281 1/20 0.33
HSD17B10 Q99714 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897578 0.92 RXRA (0.53) RXRANR1H2NR1H3PIN1ALDH1A1
SCHEMBL4899625 0.92 RXRA (0.42) RXRANR1H2NR1H3PIN1ALDH1A1
SCHEMBL4897129 0.91 KDM4E (0.46) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL4899355 0.89 RXRA (0.43) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL4905891 0.86 KDM4E (0.44) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL4902740 0.85 RXRA (0.43) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL2266868 0.84 NR1H2 (0.52) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL2387472 0.84 RXRA (0.49) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL4904765 0.84 RXRA (0.49) RXRANR1H2NR1H3ALDH1A1HPGD
SCHEMBL4902475 0.84 NR1H2 (0.47) RXRANR1H2NR1H3ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US claimed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO claimed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 RXRA 20/4885NR1H2 1/4885NR1H3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.